Manufacturer record
Geenac Pharma: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
3 batches manufactured by Geenac Pharma (Uttarakhand) were declared Not of Standard Quality between December 2024 and July 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
3 records linked to Geenac Pharma in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Cefixime & Azithromycin Tablets | MWDC-5421GMfg 2026-01 · Exp 2027-12 | Identity test negative for Cefixime & AzithromycinOther | Lucknow LabState lab | Jul 2026 |
| Jikcf-AZ Tablets, Cefixime and Azitromycin Tablets | BPT-3001Mfg 2024-02 · Exp 2026-01 | The sample does not meets the Specifications with respect to Identification test-Nil Assay-Nil As per STP u/s. 17B of Drugs and Cosmetics Act 1940. The Sample deemed to be SPURIOUS.Assay | State Lab Drugs Control Laboratory, TelanganaState lab | Dec 2024 |
| Jakclav-625 Tablets, Amoxicillin and Potassium Clavulanate Tablets | BPT-3002Mfg 2024-02 · Exp 2026-01 | The sample Does not meet the Specifications wrt. Identification test - Negative, Assay- Nil As per IP u/s. 17B of Drugs and Cosmetics Act 1940. the Sample deemed to be SPURIOUS and Misbranded.Assay | State Lab Drugs Control Laboratory, TelanganaState lab | Dec 2024 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.